Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 20/20 | 0.55 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29986084 | 1.00 | IRAK4 (0.55) | IRAK4IRAK1 | |
| Hydrochloric Acid SCHEMBL16898978 | 0.99 | IRAK4 (0.54) | IRAK4IRAK1 | |
| SCHEMBL16899041 | 0.94 | IRAK4 (0.54) | IRAK4 | |
| SCHEMBL16899141 | 0.93 | IRAK4 (0.54) | IRAK4 | |
| Hypochlorous Acid SCHEMBL20787534 | 0.93 | IRAK4 (0.54) | IRAK4 | |
| Hydrochloric Acid SCHEMBL16898967 | 0.93 | IRAK4 (0.54) | IRAK4IRAK1 | |
| SCHEMBL16899252 | 0.92 | IRAK4 (0.54) | IRAK4 | |
| SCHEMBL16899267 | 0.91 | IRAK4 (0.49) | IRAK4 | |
| SCHEMBL18207945 | 0.91 | IRAK4 (0.49) | IRAK4 | |
| SCHEMBL16899259 | 0.91 | IRAK4 (0.51) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4319750-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Curis, Inc. (US) | 2024-02-14 | — | — | EP | claimed |
| CN-117120054-A | Combination therapy for the treatment of cancer | 柯里斯公司 | 2023-11-24 | — | — | CN | claimed |
| EP-3704108-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Curis, Inc. (US) | 2020-09-09 | — | — | EP | claimed |
| CN-111225911-A | Compounds and compositions for treating hematological disorders | 库里斯公司 | 2020-06-02 | — | — | CN | claimed |
| EP-3600270-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Aurigene Discovery Technologies Limited (IN) | 2020-02-05 | — | — | EP | claimed |
| CN-110691589-A | Compounds and compositions for treating hematological disorders | 奥列基因发现技术有限公司 | 2020-01-14 | — | — | CN | claimed |
| EP-3092226-B1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2019-03-13 | — | — | EP | claimed |
| WO-2018178947-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-10-04 | — | — | WO | claimed |
| EP-3092226-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-11-16 | — | — | EP | claimed |
| WO-2015104662-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | claimed |
| EP-4410377-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Curis, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4252853-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Aurigene Oncology Limited (IN) | 2023-10-04 | — | — | EP | disclosed |
| US-20220331297-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2022-10-20 | — | — | US | disclosed |
| US-11419875-B2 | Compounds and compositions for treating hematological disorders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-08-23 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190134010-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | CURIS, INC. | 2019-05-09 | — | — | US | disclosed |
| EP-3092226-B1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2019-03-13 | — | — | EP | disclosed |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-10 | — | — | US | disclosed |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885IRAK1 1/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885IRAK1 1/4885 |
| US-20220331297-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885IRAK1 1/4885 |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885IRAK1 3/4885 |
| US-11419875-B2 | Compounds and compositions for treating hematological disorders | IRAK4, FLT3, IRAK3 | IRAK4 1/4885IRAK1 6/4885 |
| US-20190134010-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | IRAK4, IRAK2, JAK2 | IRAK4 1/4885IRAK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.